Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Authors
Shridar Ganesan
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Shridar Ganesan, Gyan Bhanot, Janice M. Mehnert, Ann W. Silk, Jeffrey S. Ross, Dean Pavlick, Siraj Mahamed Ali, Paul Markowski, Howard L. Kaufman, Ryan J. Sullivan, Christine Marie Lovly, Jeffrey Alan Sosman, Douglas Buckner Johnson, Anil Betigeri, Kalyanasundaram Subramanian, Anshuman Panda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Prognostic and Predictive Markers
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 35)
DOI
10.1200/JCO.2017.35.7_suppl.35
Abstract #
35
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pan-cancer analysis of P21 activated kinase (PAK) family genes as potential biomarkers for immune checkpoint therapy.
First Author: Sun Gang
Poster
2021 ASCO Annual Meeting
Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.
First Author: Jie Gao
Poster
2021 ASCO Annual Meeting
A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
First Author: Yang Li
Poster
2021 ASCO Annual Meeting
Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes.
First Author: Kabir Mody